耐酒石酸酸性磷酸酶(ACP5)等多因子檢測試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Acid Phosphatase 5, Tartrate Resistant (ACP5) ,etc. by FLIA (Flow Luminescence Immunoassay)
TRAP; TrATPase; Tartrate Resistant Acid Phosphatase; Type 5 acid phosphatase
（注：單次混測多因子不超過8個指標(biāo) ）
- 編號LMA902Mu
- 物種Mus musculus (Mouse，小鼠)相同的名稱，不同的物種。
- 實驗方法雙抗夾心
- 反應(yīng)時長3.5h
- 檢測范圍4.88-5000pg/mL
- 靈敏度最小可檢測劑量小于等于1.627 pg/mL.
- 樣本類型serum, plasma, tissue homogenates and other biological fluids
- 下載英文說明書 中文說明書
- 規(guī)格8指標(biāo)數(shù)7指標(biāo)數(shù)6指標(biāo)數(shù)5指標(biāo)數(shù)4指標(biāo)數(shù)3指標(biāo)數(shù)2指標(biāo)數(shù)1指標(biāo)數(shù)
- 價格¥ 2427¥ 2521¥ 2661¥ 2847¥ 3034¥ 3314¥ 3734¥ 4668 添加到價格計算器 計算器
- 欲了解實際交易價格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測耐酒石酸酸性磷酸酶(ACP5)等多因子檢測試劑盒(流式熒光發(fā)光法)，經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測，因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的耐酒石酸酸性磷酸酶(ACP5)等多因子檢測試劑盒(流式熒光發(fā)光法)（加標(biāo)樣品），重復(fù)測定并計算其均值，回收率為測定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 84-101 | 88 |
| EDTA plasma(n=5) | 90-97 | 93 |
| heparin plasma(n=5) | 79-105 | 91 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對低、中、高值定值樣本進(jìn)行定量檢測,每份樣本連續(xù)測定20 次，分別計算不同濃度樣本的平均值及SD值。
批間差：選取3個不同批次的試劑盒分別對低、中、高值定值樣本進(jìn)行定量測定，每個樣本使用同一試劑盒重復(fù)測定8次，分別計算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的耐酒石酸酸性磷酸酶(ACP5)等多因子檢測試劑盒(流式熒光發(fā)光法)，并倍比稀釋成1:2，1:4，1:8，1:16的待測樣本，線性范圍即為稀釋后樣本中耐酒石酸酸性磷酸酶(ACP5)等多因子檢測試劑盒(流式熒光發(fā)光法)含量的測定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 91-98% | 99-105% | 79-102% | 86-101% |
| EDTA plasma(n=5) | 90-97% | 97-105% | 87-101% | 86-95% |
| heparin plasma(n=5) | 97-105% | 88-101% | 89-101% | 85-101% |
穩(wěn)定性
經(jīng)測定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響，實驗室的環(huán)境條件需盡量保持一致，尤其是實驗室內(nèi)溫度、濕度及溫育條件。其次由同一實驗員來進(jìn)行操作可減少人為誤差。
實驗流程
1. 實驗前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品、樣本、磁珠）標(biāo)準(zhǔn)品或樣本100μL及磁珠10μL，
37°C酶標(biāo)板振蕩器孵育90分鐘；
3. 磁吸甩干，加檢測溶液A100μL，37°C酶標(biāo)板振蕩器孵育60分鐘；
4. 磁吸洗板3次；
5. 加檢測溶液B100μL，37°C振動孵育30分鐘；
6. 磁吸洗板3次；
7. 加鞘液100μL，旋渦震蕩2分鐘后讀數(shù)。
實驗原理
將耐酒石酸酸性磷酸酶(ACP5)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體包被于磁珠，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠，其中的耐酒石酸酸性磷酸酶(ACP5)等多因子檢測試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的耐酒石酸酸性磷酸酶(ACP5)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體，將未結(jié)合的生物素化抗體洗凈后，加入PE標(biāo)記的親和素，再次徹底洗滌后即可上機(jī)讀數(shù)。MFI值和樣品中的耐酒石酸酸性磷酸酶(ACP5)等多因子檢測試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Mus musculus (Mouse，小鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPA902Mu01 | 耐酒石酸酸性磷酸酶(ACP5)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA902Mu02 | 耐酒石酸酸性磷酸酶(ACP5)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA902Mu02 | 耐酒石酸酸性磷酸酶(ACP5)多克隆抗體 | WB; IHC; ICC; IP. |
| PAA902Mu01 | 耐酒石酸酸性磷酸酶(ACP5)多克隆抗體 | WB; IHC; ICC; IP. |
| SEA902Mu | 耐酒石酸酸性磷酸酶(ACP5)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| MEA902Mu | 耐酒石酸酸性磷酸酶(ACP5)檢測試劑盒(酶聯(lián)免疫吸附試驗法,小樣本) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA902Mu | 耐酒石酸酸性磷酸酶(ACP5)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Archives of Oral Biology | Oxytocin promotes bone formation during the alveolar healing process in old acyclic female rats[ScienceDirect: S0003996912001021] |
| Life Sciences | Exendin-4 Increases Bone Mineral Density in Type 2 Diabetic OLETF Rats Potentially Through the Down-Regulation of SOST/Sclerostin in Osteocytes[PubMed: 23357248] |
| International Journal of Cardiology | Valvular osteoclasts in calcification and aortic valve stenosis severity.[Pubmed: 23452891] |
| Evidence-Based Complementary and Alternative Medicine | Antiosteoporosis Activity of New Oriental Medicine Preparation (Kyungokgo Mixed with Water Extract of Hovenia dulcis) on the Ovariectomized Mice[Pubmed:25737735] |
| Advances in Medical Sciences | The influence of bexarotene, a selective agonist of the retinoid receptor X (RXR), and tazarotene, a selective agonist of the retinoid acid receptor (RAR), on bone metabolism in rats[PubMed: 26569440] |
| Bone | The effects of strength training and raloxifene on bone health in aging ovariectomized rats[Pubmed:26812611] |
| Journal of Clinical Medicine Research | In?Vitro?and In?Vivo?Effects?of?Gracilaria?verrucosa?Extracts?on?Osteoclast?Differentiation.[pubmed:28335442] |
| Biomedicine & Pharmacotherapy | Anti-osteoporotic effects of an antidepressant tianeptine on ovariectomized rats[S0753332216322752] |
| Clinical Trials in Degenerative Diseases | Correlating oxidative stress-related factors with bone metabolic markers in older adult male patients exhibiting degenerative osteoporosis in the high-altitude hypoxic area of China: study protocol for a non-randomized controlled trial[issn:2542-3975] |
| Scientific Reports | Evidence for excessive osteoclast activation in SIRT6 null mice[Pubmed:30030453] |
| International?Journal?of?Molecular?Sciences? | Suppression Effect of Astaxanthin on Osteoclast Formation In Vitro and Bone Loss In Vivo[Pubmed:29562730] |
| Experimental Gerontology | The decline of whole-body glucose metabolism in ovariectomized rats[Pubmed: 30292771] |
| Bone?Research | NUMB maintains bone mass by promoting degradation of PTEN and GLI1 via ubiquitination in osteoblasts[Pubmed: 30455992] |
| Cell Death & Disease | QKI deficiency leads to osteoporosis by promoting RANKL-induced osteoclastogenesis and disrupting bone metabolism[Pubmed: 32382069] |
| Effect of Corticopuncture (CP), Photobiomodulation (PBM) and the Combined Method on the Rate of Tooth Movement and Root Resorption: A Molecular, Histological …[] | |
| Evid Based Complement Alternat Med | Gujiansan Ameliorates Avascular Necrosis of the Femoral Head by Regulating Autophagy via the HIF-1α/BNIP3 Pathway[34512780] |